Teva Pharmaceutical Industries Target of Unusually High Options Trading (NYSE:TEVA)

Teva Pharmaceutical Industries Limited (NYSE:TEVA) was the recipient of unusually large options trading on Wednesday. Stock traders purchased 98,415 call options on the company. This represents an increase of 240% compared to the average volume of 28,932 call options.

Teva Pharmaceutical Industries Stock Down 13.5 %

NYSE:TEVA traded down $2.90 on Wednesday, hitting $18.63. 34,945,407 shares of the company’s stock traded hands, compared to its average volume of 11,240,573. The firm has a 50-day moving average price of $19.94 and a 200-day moving average price of $18.47. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.57. Teva Pharmaceutical Industries has a 1 year low of $11.48 and a 1 year high of $22.80. The company has a market cap of $21.10 billion, a PE ratio of -21.88, a price-to-earnings-growth ratio of 1.11 and a beta of 0.73.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.92% and a negative net margin of 5.73%. Equities analysts anticipate that Teva Pharmaceutical Industries will post 2.37 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. UBS Group upped their target price on Teva Pharmaceutical Industries from $28.00 to $30.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JPMorgan Chase & Co. boosted their target price on Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Monday, October 21st. StockNews.com cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Barclays upped their price objective on shares of Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a report on Wednesday, December 18th. Finally, Piper Sandler increased their target price on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.63.

Insider Transactions at Teva Pharmaceutical Industries

In related news, EVP Christine Fox sold 19,388 shares of the firm’s stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $16.87, for a total transaction of $327,075.56. Following the completion of the sale, the executive vice president now directly owns 44,104 shares of the company’s stock, valued at approximately $744,034.48. This trade represents a 30.54 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Roberto Mignone sold 286,000 shares of Teva Pharmaceutical Industries stock in a transaction on Friday, December 20th. The stock was sold at an average price of $22.01, for a total value of $6,294,860.00. Following the sale, the director now owns 695,000 shares of the company’s stock, valued at approximately $15,296,950. This trade represents a 29.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Stifel Financial Corp grew its stake in Teva Pharmaceutical Industries by 54.0% in the third quarter. Stifel Financial Corp now owns 66,391 shares of the company’s stock valued at $1,196,000 after acquiring an additional 23,283 shares during the period. Thrivent Financial for Lutherans raised its position in Teva Pharmaceutical Industries by 21.8% in the 3rd quarter. Thrivent Financial for Lutherans now owns 224,511 shares of the company’s stock valued at $4,046,000 after buying an additional 40,218 shares during the last quarter. Sio Capital Management LLC bought a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter worth approximately $24,314,000. CWA Asset Management Group LLC bought a new stake in shares of Teva Pharmaceutical Industries in the fourth quarter worth $3,340,000. Finally, Two Sigma Advisers LP grew its position in Teva Pharmaceutical Industries by 15.3% in the third quarter. Two Sigma Advisers LP now owns 1,034,500 shares of the company’s stock valued at $18,642,000 after purchasing an additional 137,000 shares in the last quarter. Institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.